Leaders in Pharmaceutical Business Intelligence (LPBI) Group

4:30 8/29 PANEL DISCUSSION: ONCOLYTIC IMMUNOTHERAPY IN THE ERA OF CHECKPOINT BLOCKADE @IMMUNO-ONCOLOGY SUMMIT – AUGUST 29-30, 2016 | Marriott Long Wharf Hotel – Boston, MA

http://www.immuno-oncologysummit.com/uploadedFiles/Immuno_Oncology_Summit/Agenda/16/2016-The-Immuno-Oncology-Summit-Brochure.pdf

Leaders in Pharmaceutical Business intelligence (LPBI) Group covers in Real Time the IMMUNO-ONCOLOGY SUMMIT using Social Media

Aviva Lev-Ari, PhD, RN,

Founder, LPBI Group & Editor-in-Chief

http://pharmaceuticalintelligence.com

Streaming LIVE @ Marriott Long Wharf Hotel in Boston

Curation of Scientific Content @Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston

4:30 8/29 PANEL DISCUSSION: ONCOLYTIC IMMUNOTHERAPY IN THE ERA OF CHECKPOINT BLOCKADE

Robert Coffin, Ph.D., CEO,

Replimmune Ltd Oncolytic immunotherapy treats cancer by virus-mediated tumor cell lysis and generation of a patient specific cancer vaccine, including to neo-antigens, in situ directly in the patient. Both are likely important for the clinical efficacy seen with single agent use, and also for the clinical synergy observed with immune checkpoint blockade. Background and data supporting single agent and combination use will be discussed, and future directions described.

• synergistic with other therapies
• 15 years of basic research now is available

David Kirn, MD, CEO, 4D Molecular Therapeutics

• comnibation VT with IT
• deliver into the tumor MDs are not agents og change, oral drug IV, IT injections intratumorally by Interventional Radiology is a fight worth fighting
• Ovarian cancer – injection was a strugle
• injection in to the eye is now the practice
• IV
• Angiogenic paradigm was throughn out
• synergies with antivascular

Mattew Mulvey, PhD, CEO, BeneVir

• consensus was IV ot iT
• IT dosing targeting the tumor for IV dosing –  need ne IT in present time
• Interested in the microboome, manipulate to achieve goals,
• consolidation in the industry is unavaidable

John Bell, PhD, University of Ottawa

• approval of single agent will change
• viral particles to be used

Stephen Russell, MD, PhD, Mayo Clinic and VYRID

• OV is the main event, other IT will be used in conjunction with OT which will LEAD the Therapy 
• vascular enthotelium
• cell therapyas carriers will act like vessels
• Systemic delivery from AMGEN, Phase III is a proof
• cycle of drug approval is 15 years, good is the enemy of Better, minor improvals are nmany